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AbstrACt
Introduction Annually, millions of adults suffer hip 
fractures. The mortality rate post a hip fracture is 7%–
10% at 30 days and 10%–20% at 90 days. Observational 
data suggest that early surgery can improve these 
outcomes in hip fracture patients. We designed a clinical 
trial—HIP fracture Accelerated surgical TreaTment 
And Care tracK (HIP ATTACK) to determine the effect of 
accelerated surgery compared with standard care on the 
90-day risk of all-cause mortality and major perioperative 
complications.
Methods and analysis HIP ATTACK is a multicentre, 
international, parallel group randomised controlled 
trial (RCT) that will include patients ≥45 years of age 
and diagnosed with a hip fracture from a low-energy 
mechanism requiring surgery. Patients are randomised to 
accelerated medical assessment and surgical repair (goal 
within 6 h) or standard care. The co-primary outcomes 
are (1) all-cause mortality and (2) a composite of major 
perioperative complications (ie, mortality and non-fatal 
myocardial infarction, pulmonary embolism, pneumonia, 
sepsis, stroke, and life-threatening and major bleeding) at 
90 days after randomisation. All patients will be followed 
up for a period of 1 year. We will enrol 3000 patients.
Ethics and dissemination All centres had ethics approval 
before randomising patients. Written informed consent is 
required for all patients before randomisation. HIP ATTACK 
is the first large international trial designed to examine 
whether accelerated surgery can improve outcomes 
in patients with a hip fracture. The dissemination plan 
includes publishing the results in a policy-influencing 
journal, conference presentations, engagement of 
influential medical organisations, and providing public 
awareness through multimedia resources.
trial registration number NCT02027896; Pre-results.
IntroduCtIon 
Worldwide, millions of adults suffer a hip 
fracture annualy.1 A hip fracture results in 
trauma, pain, bleeding and immobility. These 
strengths and limitations of this study
 ► HIP fracture Accelerated surgical TreaTment And 
Care tracK (HIP ATTACK) is the first large  randomised 
controlled trial powered to determine the effects of 
accelerated surgery compared with the standard of 
care in hip fracture patients.
 ► HIP ATTACK trial implemented patient engagement 
strategies, including research governance, trial out-
come evaluation and knowledge translation.
 ► Patients, healthcare providers and study personnel 
are unblinded to patient treatment allocation; how-
ever, outcome adjudicators are blinded to treatment 
allocation.
 ► HIP ATTACK will only inform the effect of accelerated 
surgery versus standard care during hospital work-
ing hours and does not inform the effects outside of 
working hours.
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factors may trigger inflammation, hypercoagulability, 
catabolism and stress,2–5 which can precipitate periopera-
tive complications. The most commonly reported causes 
of short-term mortality after a hip fracture are coronary 
heart disease, stroke, pneumonia, sepsis and pulmonary 
embolism.6 7 The mortality rate post a hip fracture is 7% 
to 10% at 30 days and 10% to 20% at 90 days.8–13 
The impact of early surgery on the risk of periopera-
tive complications and mortality in hip fracture patients 
was evaluated in a systematic review and meta-analysis of 
observational studies.14 Earlier surgery was associated with 
a significant reduction in mortality (relative risk [RR], 
0.81; 95% CI 0.68 to 0.96; p=0.01) in five studies (4208 
patients,721 deaths). Earlier surgery was also associated 
with reduced risk of pressure sores (RR, 0.48; 95% CI 0.34 
to 0.69; p<0.001) and in-hospital pneumonia (RR, 0.59; 
95% CI 0.37 to 0.93; p=0.02).14
The HIP fracture Accelerated surgical TreaTment And 
Care tracK (HIP ATTACK) Pilot Trial included 60 patients 
and established the feasibility of a trial of accelerated 
surgery in patients with a hip fracture. Among patients 
randomised to accelerated surgery, 30% had a major 
perioperative complication (ie, mortality and non-fatal 
preoperative myocardial infarction [MI], myocardial 
injury after noncardiac surgery, pulmonary embolism, 
pneumonia, stroke, and life-threatening and major 
bleeding) within 30 days of randomisation as compared 
with 47% of the patients allocated to standard care (HR , 
0.60; 95% CI 0.26 to 1.39; p=0.23).15
We designed the HIP ATTACK Trial to determine the 
effect of accelerated medical clearance and accelerated 
surgery compared with standard care on the 90-day 
risk of the following two co-primary outcomes: all-cause 
mortality and major perioperative complications.
MEthods And AnAlysIs
trial design
The HIP ATTACK Trial is a multicentre international, 
parallel group randomised controlled trial (RCT) of 3000 
patients with a hip fracture that requires a surgical inter-
vention. Patients are randomised to accelerated medical 
assessment and surgical repair (ie, goal of surgery within 
6 hours of hip fracture diagnosis) or standard care.
trial population
We include patients ≥45 years of age who were diagnosed 
with a hip fracture during working hours, due to a low-en-
ergy mechanism, and requiring surgery. All centres are 
able to define their own study working hours according to 
the feasibility of randomising patients to the accelerated 
surgery within 6 hours from diagnosis. Box 1 reports the 
exclusion criteria.
Currently, across Canada, 80%–90% of patients with 
a hip fracture undergo hip surgery within 48 hours after 
the diagnosis.16 To minimise the variation in the timing of 
surgery between centres, we have only included centres 
that have >80% of their hip fracture patients undergoing 
surgery within 48 hours.
Patient recruitment
Emergency department physicians and nurses receive 
a trial in-service, during which we encourage them to 
triage patients with a potential hip fracture for rapid 
assessment during working hours, similar to how patients 
with a potential MI or stroke are rapidly assessed. The 
radiology department expedites imaging of all potential 
hip fractures during working hours. Immediately on diag-
nosing a hip fracture, the emergency department physi-
cian consults the orthopaedic team on call and informs 
the HIP ATTACK research team about the patient. 
After reviewing the films and confirming a hip fracture 
requiring surgical intervention, the orthopaedic surgeon 
immediately informs the study personnel. Research 
personnel approach all eligible patients to participate in 
the trial.
randomisation and blinding
Randomisation occurs immediately after a patient 
is deemed eligible and written informed consent is 
obtained. Research personnel randomise the patients via 
an Interactive Web Randomisation System (IWRS). The 
IWRS is a 24 hours computerised randomisation internet 
system maintained by the coordinating centre at the 
Population Health Research Institute (PHRI), which is 
part of Hamilton Health Sciences and McMaster Univer-
sity in Hamilton, Ontario, Canada.
The randomisation process uses block randomisation 
stratified by the centre and by the type of planned surgery 
(open reduction and internal fixation; or arthroplasty). 
We use randomly varying block sizes; the study personnel 
and investigators are not aware of the exact sizes. We 
randomise patients in a 1:1 fashion to receive accelerated 
box 1 Exclusion criteria of the hIP AttACK trial
Patients fulfilling any of the following criteria are excluded:
 ► Requiring emergent surgery or emergent interventions for anoth-
er reason (eg, subdural hematoma, abdominal pathology requiring 
urgent laparotomy, acute limb ischemia, other fractures or trauma 
requiring emergent surgery, necrotising fasciitis, coronary revascu-
larisation, pacemaker-implantation).
 ► Open hip fracture.
 ► Bilateral hip fractures.
 ► Peri-prosthetic fracture.
 ► Therapeutic anticoagulation not induced by a vitamin K antagonist, 
unfractionated heparin (eg, any administration of therapeutic low 
molecular weight heparin [>6000 u/24 hours] in the 24 hours prior 
to enrolment) or intake of any other oral anticoagulant(s) for which 
there is no reversing agent available.
 ► Taking a therapeutic vitamin K antagonist with a history of hepa-
rin-induced thrombocytopaenia.
 ► Refusing participation.
 ► Previously enrolled in the trial.
HIP ATTACK , HIP fracture Accelerated surgical TreaTment And Care tracK.
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medical clearance and accelerated surgery versus standard 
care (figure 1). The randomisation procedure ensures 
concealment for the purpose of minimising bias. Due to 
the nature of the trial, it is not possible to blind research 
personnel, participants or care providers involved in 
a patient’s care. Outcome assessors are blinded to the 
trial intervention.
trial intervention
Patients randomised to accelerated care undergo medical 
clearance by a medical specialist (ie, internist, geriatri-
cian, cardiologist or anaesthesiologist), who is available 
to quickly arrive in the emergency department for the 
assessment. This specialist uses his/her own individual 
judgement regarding management when considering 
any medical conditions identified, and weighs the poten-
tial benefits of delaying surgery for medical management 
versus the potential negative consequences of protracted 
exposure to the inflammatory, hypercoagulable, stress 
and catabolic states associated with a hip fracture. The 
medical specialist is aware of all the conditions that the 
trial consensus group believe are likely to benefit from 
medical optimisation before surgery (box 2).
Following medical clearance, the orthopaedic surgeon 
and anaesthesiologist need to agree that the patient is 
appropriate for surgery for the case to proceed. Patients 
randomised to accelerated care (ie, medical clearance 
and surgery), who are therapeutically anticoagulated with 
a vitamin K antagonist, receive prothrombin complex 
concentrate to target an International Normalised Ratio 
(INR) <1.5.
Patients randomised to accelerated care, after obtaining 
medical clearance, move into the next orthopaedic 
trauma room or elective operating room slot depending 
on availability (ie, they are prioritised over scheduled 
elective cases). In centres with a dedicated trauma room, 
there is minimal impact to the workflow with case prior-
ities being adjusted to accommodate the HIP ATTACK 
case booking. In addition, on evenings or weekends, HIP 
ATTACK patients are prioritised over other non-urgent 
emergency cases. Immediately after medical clearance 
is obtained, research personnel inform all the relevant 
stakeholders (ie, surgical booking clerk, orthopaedic 
surgeon and anaesthesiologist) to facilitate the exchange 
of the elective and the accelerated hip fracture case. The 
scheduled elective cases shift a slot forward, and there-
fore they occur a few hours later than originally planned.
Patients randomised to standard care undergo medical 
clearance based on local standard practices. After the 
patient is medically cleared, he/she is waitlisted for 
surgery according to local standard practices.
Figure 1 The HIP ATTACK RCT flow chart. ECG, electrocardiogram; HIP ATTACK, HIP fracture Accelerated surgical TreaTment 
And Care tracK; NPO, nil per os; OR, operating room; RCT, randomised controlled trial. 
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The central data management team monitors data 
quality, adherence to the trial intervention and provides 
a feedback to local investigators to ensure adherence to 
the protocol.
Co-interventions
For patients undergoing arthroplasty, the choice of 
the surgical implant is left to the surgeon’s discretion 
in both accelerated and standard care groups. All other 
perioperative management (monitoring, fluids, type of 
anaesthesia, analgesia and transfusions) and postopera-
tive care are at the discretion of the attending anaesthesi-
ologist, surgeon and medical specialist. Study personnel 
record data on co-interventions. Study investigators 
strongly encourage appropriate venous thromboembo-
lism prophylaxis in all randomised patients. We also advo-
cate early mobilisation within 12 hours of hip surgery in 
all randomised patients, unless medically or surgically 
contraindicated.
Follow-up
All trial patients receive the same structured follow-up 
assessment. Research personnel follow patients 
throughout their time in hospital evaluating them, 
reviewing their medical records, ensuring trial orders 
are followed and noting any outcomes. The research 
personnel contact the patients by telephone at 30 days, 90 
days and 1 year after randomisation. If patients indicate 
that they have experienced an outcome, the study team 
obtains the appropriate documentation.
To accurately capture perioperative MI, we obtain daily 
troponin measurements until day 7 after randomisation. 
Research personnel screen all patients for postopera-
tive delirium applying the confusion assessment method 
(CAM)17 18 daily from day 1 to 7 after randomisation. 
Study personnel administer the short form quality of life 
(SF-36) questionnaire19 to address patients’ quality of life 
at baseline, 30 days, and 1 year after randomisation. Func-
tional independence measure (FIM) motor domain is 
determined at 30 days and 1 year, as validated in hip frac-
ture patients.20 The phone administration of the SF-36 
questionnaire has also been validated in hip arthroplasty 
patients.21 Research personnel are trained in admin-
istering the CAM, FIM and SF-36. Research personnel 
record all the trial data on case report forms with infor-
mation entered directly into an electronic data capture 
programme (iDataFax).
trial outcomes
There are two primary outcomes: (1) all-cause mortality 
at 90 days after randomisation and (2) composite of major 
perioperative complications (ie, mortality, and non-fatal 
MI, pulmonary embolism, pneumonia, sepsis, stroke, 
and life-threatening and major bleeding) at 90 days after 
randomisation.
Individual secondary outcomes at 90 days after rando-
misation include all-cause mortality, vascular mortality, 
non-vascular mortality, MI, myocardial injury after rando-
misation not meeting the third universal definition of 
MI),22–24 cardiac revascularisation procedure (ie, percu-
taneous coronary intervention or coronary artery bypass 
grafting surgery), congestive heart failure, new clinically 
important atrial fibrillation, non-fatal cardiac arrest, 
stroke, peripheral arterial thrombosis, pulmonary embo-
lism, deep venous thrombosis, pneumonia, sepsis, infec-
tion, life-threatening bleeding, major bleeding, acute 
kidney injury, new acute renal failure resulting in dial-
ysis, peri-prosthetic fracture, prosthetic hip dislocation, 
implant failure, hip re-operation, time to first mobilisa-
tion, length of hospital stay, length of critical care stay, 
length of rehabilitation stay, new residence in a nursing 
home, new pressure ulcers and persistent post-surgical 
pain. Online supplementary appendix 1 describes all 
outcome definitions.
The FIM motor domain and its mobility and locomo-
tion subscores, and the SF-36 score are assessed at 30 
days after randomisation.19 25 An additional secondary 
outcome is delirium up to 7 days after randomisation. We 
determine the presence of delirium using CAM, which is 
a validated tool for the detection of delirium in elderly 
hospitalised patients.17 18 For the diagnosis of delirium, 
the CAM requires acute fluctuating changes in mental 
status, including inattention, incoherent thoughts and 
alterations in the consciousness level.17
The motor domain of FIM consists of 13 items each 
scored 1 to 7.26 The motor domain scores range from 13 
box 2 Conditions likely to benefit from medical 
optimisation prior to surgery
 ► Acute myocardial infarction associated with a mechanical complica-
tion or ST-elevation myocardial infarction.
 ► Cardiac arrest.
 ► Cardiogenic shock or frank pulmonary oedema.
 ► Respiratory failure requiring mechanical ventilation.
 ► Known pulmonary artery hypertension (>80 mmHg).
 ► Home oxygen therapy with concomitant clopidogrel.
 ► Presumptive bacteremia.
 ► Hereditary or acquired coagulopathy that cannot be corrected within 
2 hours to an INR <1.5.
 ► Thrombocytopaenia (platelets <75 ×109/L) of unknown origin that 
cannot be corrected within 2 hours or in case of known chronic 
thrombocytopaenia with Platelets <50 ×109/L.
 ► Deep venous thrombosis in the last month requiring implantation of 
vena cava filter.
 ► Acute stroke within 7 days of fracture.
 ► Subarachnoid haemorrhage within 1 month of fracture.
 ► Impaired consciousness of unknown origin (GCS<12).
 ► Fractures during seizure without known history of epilepsy.
 ► Na<120 mmol/L or  >155 mmol/L; or Na<125 mmol/L 
or >150 mmol/L with neurological symptoms.
 ► K>5.5 mmol/L with QRS-complex  >120 ms in patients without 
known previous QRS-complex  >120 ms or K<2.8 mmol/L not 
amenable to correction within 2 hours.
 ► pH<7.15, not amenable to correction within 2 hours.
 ► Indication for acute dialysis.
GCS, Glasgow Coma Scale; INR, International normalised ratio.
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to 91, with high scores indicating higher function. The 
SF-36 measures health-related quality of life by scoring 
eight domains (physical function, role limitation due 
to physical health, pain, general health perception, 
vitality, social function, role limitations due to emotional 
health and mental health) from 0 to 100. High scores 
indicate good quality of life. The validity of the SF-36 in 
patients following a hip fracture is established, as well as 
responsiveness to changes in the SF-36 physical function 
domain.19 25
outcomes at 1 year
For long-term follow-up, the primary outcome is a 
composite at 1 year after randomisation of all-cause 
mortality and non-fatal MI, pulmonary embolism, pneu-
monia, sepsis and stroke. Individual secondary 1-year 
follow-up outcomes include all-cause mortality, vascular 
mortality, non-vascular mortality, MI, congestive heart 
failure, non-fatal cardiac arrest, coronary revascularisa-
tion, stroke, peripheral arterial thrombosis, pulmonary 
embolism, deep venous thrombosis, pneumonia, sepsis, 
new acute renal failure requiring dialysis, peri-prosthetic 
fracture, prosthetic hip dislocation, implant failure, hip 
re-operation, new residence in a nursing home, hospital 
readmission, persistent postsurgical pain, FIM motor 
domain and its mobility and locomotion subscores, and 
the SF-36 score.
Adjudication of outcomes
The Event Adjudication Committee is a committee of 
clinicians with expertise in perioperative outcomes. 
These individuals are blinded to treatment allocation 
and adjudicate the following outcomes: myocardial injury 
after randomisation, MI, non-fatal cardiac arrest, stroke, 
pulmonary embolism, deep vein thrombosis, new conges-
tive heart failure, pneumonia, sepsis and bleeding. All 
adjudicators are trained before commencing trial adjudi-
cation. We will use the decisions of the outcome adjudica-
tors for all statistical analyses of these events.
Statistical considerations
Sample size
The overall type 1 error rate for the two co-primary 
outcomes will be 5% (0.05) and this will be partitioned 
between the two co-primary outcomes, taking into account 
the overlap between the outcomes (ie, all-cause mortality 
is a subset of the composite). Assuming a 20% overlap, 
with the pre-specified α of 0.04 for the first co-primary 
outcome (all-cause mortality at 90 days), the α of 0.012 for 
the second co-primary outcome (composite) was calcu-
lated via simulation.
The sample size calculations were performed using a 
time-to-event analysis (Cox proportional hazards model 
comparison with two equal groups), two-sided α=0.05 
using Power Analysis and Sample Size software V.13 
(2014) (see table 1).
With a sample size of 3000 patients, the HIP ATTACK 
Trial will have 88% power to detect a relative risk 
reduction (RRR) of 30% (ie, a HR of 0.70) for the first 
co-primary outcome (90-day all-cause mortality) with a 
two-sided α=0.04, assuming an event rate of 13.0% in the 
control group. Even with an observed RRR of 27% (ie, a 
HR of 0.73), the trial would have 80% power for the first 
co-primary outcome. The trial will also have 99% power 
to detect a 30% RRR (ie, a HR of 0.70) for the second 
co-primary outcome assuming a standard care event 
rate of 30% with an α=0.012 (two-sided). Even with an 
observed RRR of 25% (ie, HR of 0.75), there would be 
91% power for the second co-primary outcome assuming 
an event rate of 27.5% in the control group.
Main analysis
We will analyse patients in the treatment group to which 
they are allocated, according to the intention-to-treat 
principle. We will include all patients randomised in 
these analyses, regardless of the timing of surgery. We will 
compare patients allocated to accelerated medical clear-
ance and surgery with patients allocated to standard care. 
We will present the binary analyses using the Kaplan-
Meier estimator. We will use log-rank tests to compare the 
rate of occurrence of the primary outcome between the 
accelerated care group and the standard care group. We 
will use Cox proportional hazards models to estimate the 
effect of accelerated care on the HR for the primary and 
dichotomous secondary outcomes including the 1-year 
outcomes. We will calculate the HRs and their associ-
ated 95% CIs. We will estimate the effect of accelerated 
care versus standard care on SF-36 and FIM scores with a 
generalised linear model. We will infer statistical signifi-
cance if the computed two-sided p value is <0.05.
Table 1 Sample size calculations: sample size fixed at 
3000 and α for the first co-primary outcome (mortality) fixed 
at 0.04 and the second co-primary outcome calculated at 
0.012
Power calculation
Control event rate 
Sample size fixed at 3000 and α for the first co-primary 
outcome (mortality) fixed at 0.04
  HR 12.5% 13.0% 13.5 % 
  0.73 0.785 0.801 0.816
  0.70 0.873 0.886 0.897
  0.65 0.96 0.966 0.971
Sample size fixed at 3000 and α for the second co-primary 
outcome* at 0.012 (calculated)
  HR 27.5% 30% 32.5%
  0.75 0.916 0.941 0.958
  0.70 0.988 0.993 0.996
  0.65 0.9992 0.9997 0.9999
*Composite outcome of major perioperative complications (ie, 
mortality, non-fatal myocardial infarction, pulmonary embolism, 
pneumonia, sepsis, stroke, and life-threatening and major 
bleeding).
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subgroup analysis
Cox proportional hazards model assessing the primary 
outcome will provide the basis for evaluating our single 
planned subgroup analysis (ie, patients who present to 
the hospital ≥4 hours after their hip fracture). We expect 
a larger treatment effect in patients who present within 
4 hours of their hip fracture. We will infer a subgroup 
effect if the interaction term of treatment and subgroup 
is statistically significant at p<0.05.
Interim analysis
We will perform two interim efficacy analyses based on the 
co-primary outcomes when 50% and 75% of the patients 
have been followed for 90 days. The independent Trial 
Monitoring Committee (TMC) will employ the modified 
Haybittle-Peto rule of 4 SDs (α=0.0001) for analyses in the 
first half of the trial (including the first planned interim 
analysis) and three SDs (α=0.00047) for all analyses in the 
second half. For a finding to be considered significant for 
either co-primary outcome, these predefined boundaries 
will have to be exceeded in at least two consecutive anal-
yses, three or more months apart. If either co-primary 
outcome fulfils these criteria, the TMC will consider initi-
ating discussion with the Project Ooffice Ooperations 
Ccommittee about potentially terminating the trial.
The α-level for the final analysis will remain the conven-
tional α=0.05, given the infrequent interim analyses and 
associated low α levels, as well as the requirement for 
confirmation with subsequent analyses. We will appor-
tion the α between the two co-primary outcomes in the 
final analysis. We will split the α with the first co-primary 
outcome (all-cause mortality at 90 days) at 0.04 and the 
second co-primary outcome (composite) at 0.012, due to 
overlap.
At any time during the trial, if safety concerns arise, the 
TMC chairperson will assemble a formal meeting of the 
full committee. The TMC will make their recommenda-
tions to the Project Office Operations Committee after 
considering all the available data and any external data 
from relevant studies. If a recommendation for termina-
tion is being considered the TMC will invite the Interna-
tional Operations Committee to explore all possibilities 
before a decision is made.
trial organisation
PHRI is the coordinating centre for this trial worldwide 
and is primarily responsible for the organisation of the 
trial, development of the randomisation scheme, the 
study database, data consistency checks, data analysis 
and coordination of the study centres. The trial structure 
includes the following groups: the Project Office Oper-
ations Committee, International Operations Committee, 
Steering Committee, National Coordinators, Investiga-
tors, Coordinating Centre, and Adjudication Committee.
Patient and public involvement
Our approach to patient engagement is guided by the 
Canadian Institutes of Health Research strategy for 
patient-oriented research patient engagement framework 
spanning research governance, strategy, and methods.27 
Examples include (a) governance auditing—-en-
gaged patient representatives maintain an audit trail of 
strategy—and execution—related decisions in order to 
guide ongoing activities; (b) ‘Word on the Street’ videos—
brief (40 to 60 s) commentaries target personal experi-
ence of our research and are shared via Twitter using Bitly 
software and (c) Outcome evaluation—we use an interac-
tive audience response system so patient partners can tell 
us, from their perspective, which trial outcomes matter 
most. We use this information to inform our future trial 
communications strategy.
EthICs And dIssEMInAtIon
We require documentation of Research Ethics Committee 
or Institutional Review Board (REC/IRB) approvals 
before sites are activated to enrol patients. All commit-
tees are described in detail in the Supplement File under 
the Supplemental Trial Groups and Investigators section. 
Investigators are informed of any protocol amendments, 
and REC/IRBs are requested to approve them. Research 
personnel or good clinical practice trained healthcare 
professionals participating in the study obtain written 
informed consent (online supplementary appendix 2) 
for each patient before randomisation. All data are stored 
on a centrally encrypted, high-security computer system 
and kept strictly confidential. The online supplementary 
appendix 3, presents the list of the HIP ATTACK trial 
participant sites and countries.
dissemination policy
The knowledge dissemination plan includes traditional 
modes of dissemination (ie, publication in a policy-driving 
journal, national/international conference presenta-
tions) as well as the engagement of influential medical 
organisations (ie, emergency medicine and orthopaedic 
surgery organisations). Broader dissemination will be 
performed by the HIP ATTACK public website (http://
www. hipattacktrial. com), Twitter account (@HIPAT-
TACKTrial), Facebook page and LinkedIn Profile. The 
Reducing Global Perioperative Risk Multimedia Resource 
Centre, linked to Elsevier’s entire online global reader-
ship, will disseminate slide and audioinstructional videos, 
full-text articles, links to abstracts and data summaries.
dIsCussIon
Hip fractures are a worldwide health concern due to 
their high incidence, poor outcomes and high health 
economic costs. Population ageing will probably worsen 
this scenario in the near future. Age, male gender, clin-
ical comorbidities, dementia, nursing home residency 
and surgical delay are associated with an increased risk 
of mortality after a hip fracture.28 Surgical timing is the 
only potential modifiable risk factor for postoperative 
mortality and major complications.
 o
n
 29 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028537 on 1 May 2019. Downloaded from 
7Borges FK, et al. BMJ Open 2019;9:e028537. doi:10.1136/bmjopen-2018-028537
Open access
Evidence from several observational studies, including 
systematic reviews and meta-analyses, demonstrates that 
early surgery is associated with better outcomes and 
with decreased mortality in patients suffering a hip frac-
ture.14 29–31 Uzoigwe and colleagues published prospec-
tive data on 2056 patients in UK. Patients who had 
surgery more than 12 hours after hip fracture diagnosis 
had adjusted OR of 3.8 (95% CI 1.03–14.50; p=0.046) 
for in-hospital mortality compared with those who had 
surgery within 12 hours.32
Results from an intervention study in Canada demon-
strated that coordinated, region-wide efforts directed at 
meeting a 48 hours benchmark for hip fracture surgery 
was successful in reducing time to surgery, length of 
stay, adjusted in-hospital and 1-year mortality.33 There 
were 3525 preintervention and 3007 postinterven-
tion patients ≥50 years of age. Surgery within 48 hours 
increased from 66.8% to 84.6%, length of stay decreased 
from 13.5 to 9.7 median days and in-hospital mortality 
decreased from 9.6% to 6.8% (all p<0.001). In-hospital 
mortality (HR, 0.68; 95% CI 0.57 to 0.81) and mortality 
at 1-year follow-up (HR, 0.87; 95% CI 0.79 to 0.96) were 
reduced in adjusted analyses.
Hip fracture patients who undergo surgery have worse 
outcomes compared with matched patients who undergo 
elective hip surgery.34 This suggests that a hip fracture 
initiates processes that increase patients’ risk indepen-
dent of surgery. A hip fracture causes pain, immobilisation 
and bleeding, which trigger a cascade of inflammation, 
sympathetic activation, hypercoagulability and catabolism 
that can ultimately cause acute clinical complications (eg, 
thromboembolism, acute MI, infection and death). Delay 
in repairing a hip fracture will increase the duration of 
time a patient is exposed to these negative physiological 
stressors. It is possible that urgent surgical treatment 
of a hip fracture will yield benefit, similar to how rapid 
treatment of an acute MI and stroke have yielded benefit 
from rapid reversal of the underlying physiological 
abnormalities.
Although previous hip fracture studies provide insights 
into this issue, there are many examples of risk-adjusted 
observational studies reporting misleading results. For 
example, observational studies suggested harm with 
transfusion of older blood; however, subsequent large 
RCTs showed older blood was safe.35 Currently, evidence 
on best timing to perform hip fracture surgery is based 
mostly on observational studies, which are at risk of 
residual confounding. These studies may have overesti-
mated the effects of early surgery because sicker patients 
likely went to surgery later than less ill patients, due to 
clinical optimisation before surgery. On the other hand, 
observational data could underestimate the effects 
of ultra-early surgery, such as surgery within 6 hours, 
which has not been evaluated in clinical studies. Only 
large, high-quality RCTs can minimise bias and provide a 
valid estimate of treatment effects.
In HIP ATTACK, the goal in the accelerated surgery 
arm is to operate on patients as soon as possible, with 
a target time of <6 hours, which was demonstrated as 
feasible in the HIP ATTACK pilot.15 HIP ATTACK is a 
large international trial powered to inform the effect of 
accelerated surgery on patient-important outcomes.
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